Eptifibatide Accord
Authorised
This medicine is authorised for use in the European Union
eptifibatide
MedicineHumanAuthorised
Overview
This is a summary of the European public assessment report (EPAR) for Eptifibatide Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Eptifibatide Accord.
For practical information about using Eptifibatide Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Eptifibatide Accord is a medicine used to prevent a heart attack in adults. It is used in the following groups:
- patients who have unstable angina (chest pain caused by poor blood flow to the heart, that may occur at rest or without an obvious trigger);
- patients who have already had a non-Q-wave myocardial infarction (a type of heart attack), with chest pain in the last 24 hours and with abnormalities on the electrocardiogram (ECG) or signs of heart problems in the blood.
Eptifibatide Accord is given with aspirin and unfractionated heparin (other medicines that prevent blood clots).
The patients most likely to benefit from a treatment with Eptifibatide Accord are those at high risk of heart attack in the three to four days after the start of acute (sudden) angina. This includes patients who are having percutaneous transluminal coronary angiography (PTCA, a type of surgery to clear the arteries supplying the heart).
The medicine contains the active substance eptifibatide.
Eptifibatide Accord is a ‘generic medicine’. This means that Eptifibatide Accord is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Integrilin.
Eptifibatide Accord should be given by a doctor who has experience in the management of heart attacks and angina and can only be obtained with a prescription. It is available as solutions for infusion (drip) and injection into a vein.
The recommended dose is 180 micrograms per kilogram body weight given as an injection into a vein as soon as possible after diagnosis. This is followed by a continuous infusion of 2.0 microgram/kg per minute which is continued for up to 72 hours, until the start of heart surgery, or until discharge from the hospital, whichever occurs first. If the patient undergoes a percutaneous coronary intervention (PCI or angioplasty, a surgical procedure that is used to unblock narrowed coronary arteries), infusion of Eptifibatide Accord can be continued for up to 24 hours after the procedure, with a maximum treatment duration of 96 hours.
Patients who have moderately reduced kidney function should receive a lower dose during the infusion. Eptifibatide Accord must not be used in patients with severe kidney problems.
Eptifibatide Accord is an inhibitor of platelet aggregation. This means that it helps to prevent cells in the blood called platelets sticking together (aggregating). This sticking together of platelets is an important step in forming a blood clot, and when it happens in the blood vessels supplying the heart it can lead to a heart attack. The active substance in Eptifibatide Accord, eptifibatide, stops the platelets aggregating by blocking a protein called glycoprotein IIb/III on their surface that helps make them sticky. This reduces the risk of a blood clot forming and helps prevent heart attacks.
The company provided data from the published literature on eptifibatide. No additional studies were needed as Eptifibatide Accord is a generic medicine that is given by injection and infusion into a vein and contains the same active substance as the reference medicine, Integrilin.
Because Eptifibatide Accord is a generic medicine, its benefits and risks are taken as being the same as the reference medicine’s.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Eptifibatide Accord has been shown to be comparable to Integrilin. Therefore, the CHMP’s view was that, as for Integrilin, the benefit outweighs the identified risk. The Committee recommended that Eptifibatide Accord be approved for use in the EU.
A risk management plan has been developed to ensure that Eptifibatide Accord is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Eptifibatide Accord, including the appropriate precautions to be followed by healthcare professionals and patients.
Further information can be found in the Eptifibatide Accord : EPAR - Risk-management-plan summary.
The European Commission granted a marketing authorisation valid throughout the European Union for Eptifibatide Accord on 11 January 2016.
For more information about treatment with Eptifibatide Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Product information
Latest procedure affecting product information: IA/0017
21/04/2023
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Eptifibatide Accord
- Active substance
- eptifibatide
- International non-proprietary name (INN) or common name
- eptifibatide
- Therapeutic area (MeSH)
- Myocardial Infarction
- Anatomical therapeutic chemical (ATC) code
- B01AC16
Pharmacotherapeutic group
Antithrombotic agentsTherapeutic indication
Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.
Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.
Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty).
News on Eptifibatide Accord
This page was last updated on